According to the National Center for Advancing Translation Sciences, there are 7,000 identified rare diseases and 95% have no approved therapies. Anviron specializes in partnering with world-class research institutions, identifying and securing the most promising orphan disease therapies, and developing these therapies for difficult to treat illnesses.
We are a team of entrepreneurial and passionate scientists, doctors, and clinicians that are dedicated to bringing promising therapies to light.
IN THE NEWS
Sept 23, 2020 - University of California San Diego & Anviron announce agreement to exclusively license to commercialize novel natural regulatory T-Cell stimulators shown to reduce chronic and acute vacillatory conditions in vitro.
Dec 28, 2020 - University of Tennessee Research Foundation & Anviron announce agreement to an exclusive, world-wide license to commercialize a novel low toxicity DPAGT-1 inhibitor with demonstrated in vivo efficacy against pancreatic cancer tumors.
Feb 16, 2021 - Translational Research at UCSD Tackles Inflammatory Disease With Promise of a New Peptide Therapeutic - Professor Alessandra Franco, MD, PhD, of the University of California, San Diego, leads researchers in identifying Fc peptides that promote adaptive immune regulation and provide a novel alternative to current autoimmune disease therapeutics.
Mar 18, 2021 - UTRF, UTHSC, and Anviron Partner to Commercialize Novel Treatment for Pancreatic Cancer - The University of Tennessee Research Foundation, the University of Tennessee Health Science Center and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors.